Medtronic's Chief Executive Fights Drug Safety Controversies
Medtronic's Chief Executive Fights Drug Safety Controversies, Sees Huge Market Opening In India
Omar Ishrak took the helm of Medtronic at a time when the medical device giant was hitting the shoals.,Air Jordan Shoes, Its mainstay business of devices to treat sudden cardiac death was stagnant, but the real problem was in the company’s spine business: bought as a way to deliver more growth, it was instead hurting as one product after another got hurt by studies questioning its benefit.
The biggest hit came just as Ishrak arrived at Medtronic from General Electric. The Spine Journal published a paper saying that side effects for Infuse, a protein drug used to cause bone growth, were not properly included in medical journal articles. Ishrak took a radical step: he hired a group including Yale’s Harlan Krumholz,,cheap adidas shoes, known for his criticisms of Merck’s Vioxx and Vytorin, and Ezekiel Emmanuel, a former health care advisor to Barack Obama, to head up an independent analysis of the data. He says that he needed to find the toughest critics possible in order to have credibility.
In the U.,Nike shox shoes,S., it’s pretty clear that Medtronic is being buffetted by a wave in which insurance companies, regulators, and doctors and patients themselves are demanding more proof that new treatments actually work. This demand for new data has affected every other company in the medical space, from Pfizer and GlaxoSmithKline to Amgen and Boston Scientific. Ishrak thinks he can still manuever in that environment.,BlackBerry Wholesale, More than that, he thinks that he can find new growth in emerging markets like India, which he says could represent an additional $3 billion in sales all on its own. Can he prove it?
My interview with Ishrak is embedded in this post. You can also watch it here.
Medtronic's Chief Executive Fights Drug Safety Controversies, Sees Huge Market Opening In India
Omar Ishrak took the helm of Medtronic at a time when the medical device giant was hitting the shoals.,Air Jordan Shoes, Its mainstay business of devices to treat sudden cardiac death was stagnant, but the real problem was in the company’s spine business: bought as a way to deliver more growth, it was instead hurting as one product after another got hurt by studies questioning its benefit.
The biggest hit came just as Ishrak arrived at Medtronic from General Electric. The Spine Journal published a paper saying that side effects for Infuse, a protein drug used to cause bone growth, were not properly included in medical journal articles. Ishrak took a radical step: he hired a group including Yale’s Harlan Krumholz,,cheap adidas shoes, known for his criticisms of Merck’s Vioxx and Vytorin, and Ezekiel Emmanuel, a former health care advisor to Barack Obama, to head up an independent analysis of the data. He says that he needed to find the toughest critics possible in order to have credibility.
In the U.,Nike shox shoes,S., it’s pretty clear that Medtronic is being buffetted by a wave in which insurance companies, regulators, and doctors and patients themselves are demanding more proof that new treatments actually work. This demand for new data has affected every other company in the medical space, from Pfizer and GlaxoSmithKline to Amgen and Boston Scientific. Ishrak thinks he can still manuever in that environment.,BlackBerry Wholesale, More than that, he thinks that he can find new growth in emerging markets like India, which he says could represent an additional $3 billion in sales all on its own. Can he prove it?
My interview with Ishrak is embedded in this post. You can also watch it here.
